30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: DePuy Synthes/Johnson & Johnson

4Q13 orthopaedic revenue: $2,456MM, +4% (U.S. +5%, ex-U.S. +4%)

  • Hips +5% (U.S. +8%, ex-U.S. +2%)
  • Knees +8% (U.S. +9%, ex-U.S. +6%)
  • Trauma +7% (U.S. +10%, ex-U.S. +4%)
  • Total Spine -2% (U.S. -5%, ex-U.S. +2%)
  • Sports Medicine +2% (U.S. +5%, ex-U.S. -2%)

 

  • Hip sales supported by strong primary stem sales, partially offset by price pressure
  • Knee growth driven by ATTUNE fixed bearing knee, partially offset by price pressure
  • Trauma sales supported by Asia Pacific growth and new products

 

2013 orthopaedic revenue: $9,509MM, +23% (U.S. $5,074MM, +22%; ex-U.S. $4,435MM, +25%)

  • Hips +4% (U.S. +6%, ex-U.S. +2%)
  • Knees +3% (U.S. +4%, ex-U.S. +2%)
  • Trauma +4% (U.S. +3%, ex-U.S. +4%)
  • Total Spine -3% (U.S. -8%, ex-U.S. +3%)
  • Sports Medicine +4% (U.S. +7%, ex-U.S. flat)

(Excluding Synthes acquisition, full year overall growth +2%)

  • Claims #1 position in trauma, #2 in spine, knees and hips